Em recrutamento
FASE
Número Europeu 2025-522209-40-00
M25-760
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer
Detalhes
Destaques